Upregulation of O‐GlcNAc transferase is involved in the pathogenesis of acute myeloid leukemia

He, Na; Ma, Daoxin; Tan, Yanjie; Liu, Min

doi:10.1111/ajco.13685

Cited by 4 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MLL-AF9 gene defects are formed by reciprocal translocation of t (9;11). Expression of MLL-AF9 fusion genes has been associated with extramedullary tumor infiltration, high recurrence rates, and low survival [ 97 ]. An example is P2X7 (P2X7 belongs to the P2X family of purinergic receptors and is aberrantly expressed in various types of malignant tumors, including leukemia) [ 98 ].…”

Section: Nsl Complexmentioning

confidence: 99%

Can O-GIcNAc Transferase (OGT) Complex Be Used as a Target for the Treatment of Hematological Malignancies?

Zhuang,

Liu,

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

The circulatory system is a closed conduit system throughout the body and consists of two parts as follows: the cardiovascular system and the lymphatic system. Hematological malignancies usually grow and multiply in the circulatory system, directly or indirectly affecting its function. These malignancies include multiple myeloma, leukemia, and lymphoma. O-linked β-N-acetylglucosamine (O-GlcNAc) transferase (OGT) regulates the function and stability of substrate proteins through O-GlcNAc modification. Abnormally expressed OGT is strongly associated with tumorigenesis, including hematological malignancies, colorectal cancer, liver cancer, breast cancer, and prostate cancer. In cells, OGT can assemble with a variety of proteins to form complexes to exercise related biological functions, such as OGT/HCF-1, OGT/TET, NSL, and then regulate glucose metabolism, gene transcription, cell proliferation, and other biological processes, thus affecting the development of hematological malignancies. This review summarizes the complexes involved in the assembly of OGT in cells and the role of related OGT complexes in hematological malignancies. Unraveling the complex network regulated by the OGT complex will facilitate a better understanding of hematologic malignancy development and progression.

show abstract

Section: Nsl Complexmentioning

confidence: 99%

Can O-GIcNAc Transferase (OGT) Complex Be Used as a Target for the Treatment of Hematological Malignancies?

Zhuang,

Liu,

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Currently, O-GlcNAc transferase (OGT) is the only known enzyme in this process affecting cell survival by modulating cell cycle and RAD52 functions. It has been proposed as a novel target in cancer therapies [147,148]. In addition, NEIL3 DNA glycosylase was extensively studied.…”

Section: Dna Damage Repair Modulated By Other Ptmsmentioning

confidence: 99%

Drug Discovery Targeting Post-Translational Modifications in Response to DNA Damages Induced by Space Radiation

Xie

Zhou

2023

IJMS

View full text Add to dashboard Cite

DNA damage in astronauts induced by cosmic radiation poses a major barrier to human space exploration. Cellular responses and repair of the most lethal DNA double-strand breaks (DSBs) are crucial for genomic integrity and cell survival. Post-translational modifications (PTMs), including phosphorylation, ubiquitylation, and SUMOylation, are among the regulatory factors modulating a delicate balance and choice between predominant DSB repair pathways, such as non-homologous end joining (NHEJ) and homologous recombination (HR). In this review, we focused on the engagement of proteins in the DNA damage response (DDR) modulated by phosphorylation and ubiquitylation, including ATM, DNA-PKcs, CtIP, MDM2, and ubiquitin ligases. The involvement and function of acetylation, methylation, PARylation, and their essential proteins were also investigated, providing a repository of candidate targets for DDR regulators. However, there is a lack of radioprotectors in spite of their consideration in the discovery of radiosensitizers. We proposed new perspectives for the research and development of future agents against space radiation by the systematic integration and utilization of evolutionary strategies, including multi-omics analyses, rational computing methods, drug repositioning, and combinations of drugs and targets, which may facilitate the use of radioprotectors in practical applications in human space exploration to combat fatal radiation hazards.

show abstract

“…Besides CLL, abnormal O-GlcNAcylation has also been reported in myelodysplastic syndrome (MDS) (Li et al 2021b), acute myeloid leukemia (AML) (He et al 2021), acute lymphoblastic leukemia (ALL) (Zhang et al 2017a), and diffuse large B-cell lymphoma (DLBC) (Pham et al 2016). Interestingly, higher OGT and OGA expression levels were observed in tumor samples and cell lines from hematological malignancies compared with those in other solid tumors (Itkonen et al 2021).…”

Section: Other Hematological Malignanciesmentioning

confidence: 99%

O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy

Zhang

Liang

et al. 2022

Mol Med

View full text Add to dashboard Cite

O-linked β-d-N-acetylglucosamine (O-GlcNAc) is an important post-translational modification of serine or threonine residues on thousands of proteins in the nucleus and cytoplasm of all animals and plants. In eukaryotes, only two conserved enzymes are involved in this process. O-GlcNAc transferase is responsible for adding O-GlcNAc to proteins, while O-GlcNAcase is responsible for removing it. Aberrant O-GlcNAcylation is associated with a variety of human diseases, such as diabetes, cancer, neurodegenerative diseases, and cardiovascular diseases. Numerous studies have confirmed that O-GlcNAcylation is involved in the occurrence and progression of cancers in multiple systems throughout the body. It is also involved in regulating multiple cancer hallmarks, such as metabolic reprogramming, proliferation, invasion, metastasis, and angiogenesis. In this review, we first describe the process of O-GlcNAcylation and the structure and function of O-GlcNAc cycling enzymes. In addition, we detail the occurrence of O-GlcNAc in various cancers and the role it plays. Finally, we discuss the potential of O-GlcNAc as a promising biomarker and novel therapeutic target for cancer diagnosis, treatment, and prognosis.

show abstract

Upregulation of O‐GlcNAc transferase is involved in the pathogenesis of acute myeloid leukemia

Cited by 4 publications

References 42 publications

Can O-GIcNAc Transferase (OGT) Complex Be Used as a Target for the Treatment of Hematological Malignancies?

Can O-GIcNAc Transferase (OGT) Complex Be Used as a Target for the Treatment of Hematological Malignancies?

Drug Discovery Targeting Post-Translational Modifications in Response to DNA Damages Induced by Space Radiation

O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy

Contact Info

Product

Resources

About